Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENDO INTERNATIONAL PLC

(ENDP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Endo International : Rolls Out Generic Version of Pfizer's Chantix in the US

09/22/2021 | 02:46pm EDT


ę MT Newswires 2021
All news about ENDO INTERNATIONAL PLC
10/05ENDO INTERNATIONAL : to Announce Third Quarter 2021 Financial Results
PR
09/30ENDO INTERNATIONAL : California judge questions counties' opioid case against drugmakers a..
RE
09/30ENDO INTERNATIONAL : Says Research Shows Prescription Drug Xiaflex May be Appropriate to T..
MT
09/30ENDO INTERNATIONAL : California judge questions counties' opioid case against drugmakers a..
RE
09/30ENDO INTERNATIONAL : Presents New Investigational Collagenase Clostridium Histolyticum (CC..
AQ
09/30Endo International plc Presents New Investigational Collagenase Clostridium Histolyticu..
CI
09/28ENDO INTERNATIONAL : Reaches Agreement in Principle to Settle Louisiana Governmental Opioi..
PR
09/28Drug distributors strike 1st opioid settlement with Native American tribe for $75 mln
RE
09/23ENDO INTERNATIONAL : Launches First and Only Generic Version of Chantix (varenicline) Tabl..
AQ
09/22Health Care Stocks Pare Gains in Late Wednesday Trade
MT
More news
Analyst Recommendations on ENDO INTERNATIONAL PLC
More recommendations
Financials (USD)
Sales 2021 2 783 M - -
Net income 2021 39,5 M - -
Net Debt 2021 6 718 M - -
P/E ratio 2021 6,79x
Yield 2021 -
Capitalization 967 M 967 M -
EV / Sales 2021 2,76x
EV / Sales 2022 2,64x
Nbr of Employees 3 397
Free-Float 98,5%
Chart ENDO INTERNATIONAL PLC
Duration : Period :
Endo International plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENDO INTERNATIONAL PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Last Close Price 4,14 $
Average target price 6,57 $
Spread / Average Target 58,7%
EPS Revisions
Managers and Directors
Blaise A Coleman President, Chief Executive Officer & Director
Mark Bradley Chief Financial Officer & Executive Vice President
Mark G. Barberio Chairman
Ruth Thorpe Chief Information Officer
Robert Polke Global Head-Operations